SCHEMBL22314932

SCHEMBL22314932

FC(F)(F)CNc1nc(-c2ccc(OC(F)(F)F)cc2)ccc1OCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.39
SCN10A Q9Y5Y9 2/20 0.39
PPARD Q03181 2/20 0.38
ACP1 P24666 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
SCN5A Q14524 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
HPGD P15428 1/20 0.37
SUCNR1 Q9BXA5 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
ENPP3 O14638 1/20 0.37
ENPP1 P22413 1/20 0.37
PRMT5 O14744 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22314935 0.82 PPARD (0.42) SCN10APPARDSUCNR1MRGPRX4
SCHEMBL22314933 0.82 ADORA2A (0.46) SCN10APPARDACP1SMN1; SMN2MAPT
SCHEMBL22314936 0.77 TRPV3 (0.42) FAAHSCN10AMAPTSCN5AKDM4E
SCHEMBL20472092 0.76 KMT2A (0.52) SCN10APPARDSMN1; SMN2MAPTMRGPRX4
SCHEMBL22314946 0.74 DGAT1 (0.50) SCN10AACP1SMN1; SMN2KDM4EALDH1A1
SCHEMBL14729755 0.72 MEN1 (0.46) FAAHSCN10APPARDACP1SMN1; SMN2
SCHEMBL5105144 0.71 MRGPRX4 (0.58) SCN10ASMN1; SMN2MAPTGAAMRGPRX4
SCHEMBL22315060 0.70 SCN10A (0.47) FAAHSCN10AACP1SMN1; SMN2KDM4E
SCHEMBL5784957 0.69 MRGPRX4 (0.63) SMN1; SMN2MAPTGAAMRGPRX4RAB9A
SCHEMBL1241715 0.68 PTGDR2 (0.47) SCN10APPARDSMN1; SMN2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20200247793-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247793-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B FAAH 921/4885SCN10A 24/4885PPARD 4182/4885
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B FAAH 921/4885SCN10A 24/4885PPARD 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.